Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission

Blood

Volumn 101, Issue 4, 2003, Pages 1611-1619

  Locatelli, Franco ^a   Labopin, Myriam ^b   Ortega, Juan ^b   Meloni, Giovanna ^b   Dini, Giorgio ^b   Messina, Chiara ^b   Yaniv, Isaac ^b   Fagioli, Franca ^b   Castel, Victoria ^b   Shaw, Peter J ^b   Ferrant, Augustin ^b   Pession, Andrea ^b   Sociè, Gerard ^b   Frassoni, Francesco ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CARMUSTINE; CYTARABINE; ETOPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW CELL; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPOGONADISM; KAPLAN MEIER METHOD; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; OUTCOMES RESEARCH; PRIORITY JOURNAL; RELAPSE; STATISTICAL ANALYSIS; STEM CELL; STEM CELL TRANSPLANTATION; THYROID DISEASE;

EID: 0037441750     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0764     Document Type: Article

References (48)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-1062.
2. Vormoor J, Boos J, Stahnke K, et al. Therapy of childhood acute myelogenous leukemia. Ann Hematol. 1996;73:11-24.
3. Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood. 1998;92:1073-1090.
4. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared to intensive chemotherapy in acute myelogenous leukemia. N Engl J Med. 1995;332:217-223.
5. Burnett AK, Goldstone AH, Stevens RMF, et al. Randomized comparison of addition autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML 10 Trial. Lancet. 1998;351:700-708.
6. Cassileth PA, Harrigton DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649-1656.
7. th AM L trial. Br J Haematol. 1998;101:30-40.
8. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med. 1996;334:1428-1434.
9. Amadori S, Testi AM, Aricò M, et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol. 1993;11:1046-1054.
10. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from Children's Cancer Group. Blood. 2001;97:56-62.
11. Bonetti F, Zecca M, Pession A, et al. Total-body irradiation and melphalan is a safe and effective conditioning regimen for autologous bone marrow transplantation in children with acute myeloid leukemia in first remission. J Clin Oncol. 1999;17:3729-3735.
12. Tiedemann K, Waters KD, Tauro GP, et al. Resuits of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission. Blood. 1993;82:3730-3738.
13. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British cooperative group. Ann Intern Med. 1985;103:620-625.
14. Meloni G, De-Fabritiis P, Petti MC, Mandelli F. BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. Blood. 1990;75:2282-2285.
15. Byar DP. Identification of prognostic factors. In: Buyse ME, Staquet MJ, Sylvester RJ, eds. Cancer clinical trials: methods and practice. Oxford, United Kingdom: Oxford Medical Publications; 1988;423-443.
16. Clift R, Goldman JM, Gratwohl A, Horowitz M. Proposal for standardized reporting of bone marrow transplantation for leukemia. Bone Marrow Transplant. 1989;4:445-448.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
18. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-202.
19. Madero L, Gonzalez-Vicent M, Ramirez M, Diaz MA. G-CSF-mobilized PBSCT in children with AML in first complete remission. Bone Marrow Transplant. 1999;23:975-976.
20. Hartmann O, Le-Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs - a randomized, controlled trial. Ann Intern Med. 1997;126:600-607.
21. Le Corroller AG, Faucher C, Auperin A, et al. Autologous peripheral blood progenitor-cell transplantation versus autologous bone marrow transplantation for adults and children with non-leukaemic malignant disease: a randomized economic study. Pharmacoeconomics. 1997;11:454-463.
22. Locatelli F, Pedrazzoli P. Recombinant human G-CSF: how wide is the field of clinical applicability? Haematologica. 1995;80:199-205.
23. Madero L, Muonz A, Diaz de Heredia A, et al. G-CSF after autologous bone marrow transplantation for malignant diseases in children: Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplant. 1995;15:349-351.
24. Saarinen UM, Hovi L, Juvonen E, Riikonen P, Mottonen M, Makipernaa A. Granulocyte-colony-stimulating factor after allogeneic and autologous bone marrow transplantation in children. Med Pediatr Oncol. 1996;26:380-386.
25. Suzue T, Takaue Y, Watanabe A, et al. Effects of rhG-CSF (filgrastim) on the recovery of hematopoiesis after high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children: a report from the Children's Cancer and Leukemia Study Group of Japan. Exp Hematol. 1994;22:1197-1202.
26. Kawano Y, Takaue Y, Mimaya J, et al. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT. Blood. 1998;92:4040-4046.
27. Schaison G, Eden OB, Henze G, et al. Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Eur J Pediatr. 1998;157:955-966.
28. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993;341:85-89.
29. Gorin NC, Labopin M, Meloni G, et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukemia. 1991;5:896-904.
30. Miller CB, Rowlings PA, Zhang MJ, et al. The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Exp Hematol. 2001;29:1336-1346.
31. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR α-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy: Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997;90:1014-1021.
32. Testi AM, Moleti ML, Del Giudice I, et al. Acute promyelocytic leukemia (APL) in children: results of the "AIDA" Italian protocol [abstract]. Blood. 2000;96(suppl 1):467.
33. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
34. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92:3515-3520.
35. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med. 1998;339:1177-1193.
36. Athale UH, Razzouk I, Raimondi SC, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood. 2001;97:3727-3732.
37. Vignetti M, Rondelli R, Locatelli F, et al. Autologous bone marrow transplantation in children with acute myeloblastic leukemia; report from the Italian National Pediatric Registry (AIEOP-BMT). Bone Marrow Transplant. 1996;18(suppl 2):59-62.
38. Ortega JJ, Olivé T, Diaz de Heredia C, et al. Allogeneic and autologous bone marrow transplantation in AML in first remission: the Spanish experience. Bone Marrow Transplant. 1996;18(suppl 2):53-58.
39. Giorgiani G, Bozzola M, Locatelli F, et al. Role of busulfan and total body irradiation on growth of pre-pubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. Blood. 1995;86:825-831.
40. Leahey AM, Teunissen H, Friedman DL, et al. Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia. Med Pediatr Oncol. 1999;32:163-169.
41. Giorgiani G, Sommaruga MG, Zecca M, et al. Thyroid complications in children given bone marrow transplantation (BMT) [abstract]. Bone Marrow Transplant. 2000;25(suppl 1):S52.
42. Michel G, Gluckman E, Esperou-Bourdeau H, et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total body irradiation - a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 1994;12:1217-1222.
43. Yaniv I, Ash S, Stark B, et al. Childhood acute myeloid leukemia: consolidation with high dose melphalan and autologous stem cell transplantation - a single centre experience [abstract]. Bone Marrow Transplant. 1997;19(suppl 1):101.
44. Cesaro S, Meloni G, Messina C, et al. High-dose melphalan in autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian pediatric group for bone marrow transplantation. Bone Marrow Transplant. 2001;28:131-136.
45. Michel G, Socié G, Gebhard F, et al. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total body irradiation - a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 1997;15:2238-2246.
46. Socie G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000;18:348-357.
47. Socie G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia: European Bone Marrow Transplantation-Severe Aplastic Anemia Working Party. N Engl J Med. 1993;329:1152-1157.
48. Curtis Re, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897-904.